A Phase 2b Study to Assess the Efficacy Safety and Tolerability of Vupanorsen (PF-07285557) in Statin-Treated Participants with Dyslipidemia
Enrolling By Invitation
40 years - 99 years
All
Phase
2
20 participants needed
1 Location
Brief description of study
Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability and PK of vupanorsen administered subcutaneously at various doses and regimens with patients with dyslipidemia.
Patients will participate for approximately 10 months, and will have blood draws, physical exams, ECGs, and MRIs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: dyslipidemia,statin
-
Age: 40 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844612
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
